TARBELA-ADNCT07781657
Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 7 → 12 locations
- Start date changed from estimate of Nov 15, 2026 to Nov 10, 2026
- Notable Recruitment opened
- Trial sites expanded: 0 → 7 locations
- Start date pushed from Oct 31, 2026 to Nov 15, 2026
- Minor Study sites: 0 to 1
- Notable Eligibility criteria expanded, about 9 words
- Secondary endpoints: details revised at 2 of 5 entries
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Change From Baseline to Week 72 in Clinical Dementia Rating, Sum of Boxes (CDR-SB)
Timeframe: From baseline up to Week 72
Secondary (5)
Change From Baseline Through Week 72 in Alzheimer's Disease Assessment Scale-Cognition 13 (ADAS-Cog-13)
Change From Baseline Through Week 72 in Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL) Total Score and Instrumental Score
Incidence of Adverse Events (AEs)
Change From Baseline in Columbia-suicide Severity Rating Scale (C-SSRS)
Plasma Concentrations of RO7568282 and its Metabolite[s]
Arms and interventions
RO7568282 High DoseExperimental
Participants will receive high dose of RO7568282.
RO7568282 Low DoseExperimental
Participants will receive low dose of RO7568282.
PlaceboPlacebo comparator
Participants will receive RO7568282 matching placebo.
Drugs: RO7568282, Placebo
Sites
12 sites in 5 countries
United States 4, Poland 3, Australia 2, France 2, Germany 1